Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 12/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384182 | 1.00 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DMAOB | |
| SCHEMBL25195364 | 0.89 | MAOB (0.45) | PDE4APDE4BPDE4CPDE4DMAOB | |
| SCHEMBL30383191 | 0.89 | GPR119 (0.45) | PDE4APDE4BPDE4CPDE4DMAOB | |
| SCHEMBL3326256 | 0.89 | GPR119 (0.45) | PDE4APDE4BPDE4CPDE4DMAOB | |
| SCHEMBL3326260 | 0.89 | GPR119 (0.45) | PDE4APDE4BPDE4CPDE4DMAOB | |
| SCHEMBL4014416 | 0.79 | PARP10 (0.43) | MAOBMAOA | |
| SCHEMBL27842239 | 0.76 | KDM1A (0.42) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25185076 | 0.72 | CYP3A4 (0.60) | MAOBMAOABCHEACHE | |
| SCHEMBL25233393 | 0.72 | CYP3A4 (0.60) | MAOBMAOABCHEACHE | |
| SCHEMBL3720859 | 0.71 | PARP10 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-2074103-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PDE4A 3506/4885PDE4B 2645/4885PDE4C 2533/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PDE4A 3576/4885PDE4B 3192/4885PDE4C 3177/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PDE4A 3576/4885PDE4B 3192/4885PDE4C 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.